keyword
https://read.qxmd.com/read/38533068/prognostic-prediction-using-a-gene-signature-developed-based-on-exhausted-t-cells-for-liver-cancer-patients
#1
JOURNAL ARTICLE
Yu Zhou, Wanrui Wu, Wei Cai, Dong Zhang, Weiwei Zhang, Yunling Luo, Fujing Cai, Zhenjing Shi
BACKGROUND: Liver hepatocellular carcinoma (LIHC) is a solid primary malignancy with poor prognosis. This study discovered key prognostic genes based on T cell exhaustion and used them to develop a prognostic prediction model for LIHC. METHODS: SingleR's annotations combined with Seurat was used to automatically annotate the single-cell clustering results of the LIHC dataset GSE166635 downloaded from the Gene Expression Omnibus (GEO) database and to identify clusters related to exhausted T cells...
March 30, 2024: Heliyon
https://read.qxmd.com/read/38531662/impact-of-immunotherapy-time-of-day-infusion-on-survival-and-immunologic-correlates-in-patients-with-metastatic-renal-cell-carcinoma-a-multicenter-cohort-analysis
#2
MULTICENTER STUDY
Jimmy S Patel, Yena Woo, Amber Draper, Caroline S Jansen, Jennifer W Carlisle, Pasquale F Innominato, Francis A Lévi, Layla Dhabaan, Viraj A Master, Mehmet A Bilen, Mohammad K Khan, Michael C Lowe, Haydn Kissick, Zachary S Buchwald, David C Qian
BACKGROUND: Recent studies have demonstrated that earlier time-of-day infusion of immune checkpoint inhibitors (ICIs) is associated with longer progression-free survival (PFS) and overall survival (OS) among patients with metastatic melanoma and non-small cell lung cancer. These data are in line with growing preclinical evidence that the adaptive immune response may be more effectively stimulated earlier in the day. We sought to determine the impact of time-of-day ICI infusions on outcomes among patients with metastatic renal cell carcinoma (mRCC)...
March 26, 2024: Journal for Immunotherapy of Cancer
https://read.qxmd.com/read/38528630/integrative-analysis-revealed-a-correlation-of-pias-family-genes-expression-with-prognosis-immunomodulation-and-chemotherapy
#3
JOURNAL ARTICLE
Qiqi Zhang, Junkui Zhang, Tianyi Lan, Jiayue He, Bin Lei, Hongnan Wang, Zhiqiang Mei, Chaoxiang Lv
BACKGROUND: Protein inhibitor of activated STATs (PIAS) has pleiotropic biological effects, such as protein post-translational modification, transcriptional coregulation and gene editing. It is reported that PIAS family genes are also correlated with immune cells infiltration in cancers that highlights their unnoticed biological role in tumor progression. However, the relationship of their expression with prognosis, immune cell infiltration, tumor microenvironment, and immunotherapy in pan-cancer has been rarely reported...
March 25, 2024: European Journal of Medical Research
https://read.qxmd.com/read/38523872/late-stage-ovarian-cancer-with-systemic-multiple-metastases-shows-marked-shrinkage-using-a-combination-of-wilms-tumor-antigen-1-wt1-dendritic-cell-vaccine-natural-killer-nk-cell-therapy-and-nivolumab
#4
Hisashi Nagai, Ryusuke Karube
A patient with bilateral ovarian cancer, peritoneal dissemination, and multiple liver and lung metastases was found with a sudden accumulation of ascites six months after delivery. Chemotherapy was started, but the prognosis was judged to be poor, so immuno-cell therapy was combined with chemotherapy. After multiple cycles of Wilms' tumor antigen 1 (WT1) dendritic cell vaccine therapy and highly activated natural killer (NK) cell therapy, the patient showed a disappearance of ascites and a remarkable reduction of multiple cancers in the whole body...
March 2024: Curēus
https://read.qxmd.com/read/38523467/current-perspectives-on-radiotherapy-in-hepatocellular-carcinoma-management-a-comprehensive-review
#5
JOURNAL ARTICLE
Dowook Kim, Jun-Sang Kim
This review examines the transformative role of external beam radiotherapy (EBRT) in managing hepatocellular carcinoma (HCC), spotlighting the progression from traditional EBRT techniques to advanced modalities like intensity-modulated radiotherapy (RT), stereotactic body RT (SBRT), and innovative particle therapy, including proton beam therapy and carbon ion RT. These advancements have significantly improved the precision and efficacy of RT, marking a paradigm shift in the multimodal management of HCC, particularly in addressing complex cases and enhancing local tumor control...
March 25, 2024: Journal of liver cancer
https://read.qxmd.com/read/38521868/single-cell-and-spatial-analyses-revealed-the-co-location-of-cancer-stem-cells-and-spp1-macrophage-in-hypoxic-region-that-determines-the-poor-prognosis-in-hepatocellular-carcinoma
#6
JOURNAL ARTICLE
Guangyu Fan, Tongji Xie, Lin Li, Le Tang, Xiaohong Han, Yuankai Shi
In hepatocellular carcinoma (HCC), classical cancer stem cells (CSC) markers were shared by normal stem cells, targeting which may hinder hepatic regeneration and cause liver failure. Additionally, the spatial structure of CSC still remained elusive. To address these limitations, we undertook a comprehensive study combining single-cell data (56,022 cells from 20 samples) and spatial data (38,191 spots from eight samples) to obtain CSC signature and uncover its spatial structure. Utilizing the CytoTRACE algorithm, we discretely identified CSC, which displayed upregulated proliferation pathways regulated by HIF1A...
March 23, 2024: NPJ Precision Oncology
https://read.qxmd.com/read/38521617/avelumab-plus-intermittent-axitinib-in-previously-untreated-patients-with-metastatic-renal-cell-carcinoma-the-tide-a-phase-2-study
#7
JOURNAL ARTICLE
Roberto Iacovelli, Chiara Ciccarese, Sebastiano Buti, Paolo Andrea Zucali, Emanuela Fantinel, Davide Bimbatti, Elena Verzoni, Caterina Accettura, Lucia Bonomi, Consuelo Buttigliero, Giuseppe Fornarini, Stefania Pipitone, Francesco Atzori, Cristina Masini, Francesco Massari, Francesca Primi, Alessandro Strusi, Giulia Claire Giudice, Matteo Perrino, Marco Maruzzo, Michele Milella, Diana Giannarelli, Matteo Brunelli, Giuseppe Procopio, Giampaolo Tortora
BACKGROUND: Combinations of vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKIs) plus immune checkpoint inhibitor (ICI) against PD1/PD-L1 are the standard first-line therapy for patients with metastatic renal cell carcinoma (mRCC), irrespective of the prognostic class. OBJECTIVE: To investigate the feasibility and safety of withdrawing VEGFR-TKI but continuing anti-PD1/PD-L1 in patients who achieve a response to their combination...
March 22, 2024: European Urology
https://read.qxmd.com/read/38520730/nanosystem-delivers-senescence-activators-and-immunomodulators-to-combat-liver-cancer
#8
JOURNAL ARTICLE
Ke Gong, Juyang Jiao, Zhihua Wu, Quan Wang, Jinghan Liao, Yi Duan, Jiangtao Lin, Jian Yu, Ying Sun, Yong Zhang, Yourong Duan
CD47 blockade has emerged as a promising immunotherapy against liver cancer. However, the optimization of its antitumor effectiveness using efficient drug delivery systems or combinations of therapeutic agents remains largely incomplete. Here, patients with liver cancer co-expressing CD47 and CDC7 (cell division cycle 7, a negative senescence-related gene) are found to have the worst prognosis. Moreover, CD47 is highly expressed, and senescence is inhibited after the development of chemoresistance, suggesting that combination therapy targeting CD47 and CDC7 to inhibit CD47 and induce senescence may be a promising strategy for liver cancer...
March 23, 2024: Advanced Science (Weinheim, Baden-Wurttemberg, Germany)
https://read.qxmd.com/read/38520717/design-of-pd-l1-targeted-lipid-nanoparticles-to-turn-on-pten-for-efficient-cancer-therapy
#9
JOURNAL ARTICLE
Yelee Kim, Jiwoong Choi, Eun Hye Kim, Wonbeom Park, Hochung Jang, Yeongji Jang, Sung-Gil Chi, Dae-Hyuk Kweon, Kyuri Lee, Sun Hwa Kim, Yoosoo Yang
Lipid nanoparticles (LNPs) exhibit remarkable mRNA delivery efficiency, yet their majority accumulate in the liver or spleen after injection. Tissue-specific mRNA delivery can be achieved through modulating LNP properties, such as tuning PEGylation or varying lipid components systematically. In this paper, a streamlined method is used for incorporating tumor-targeting peptides into the LNPs; the programmed death ligand 1 (PD-L1) binding peptides are conjugated to PEGylated lipids via a copper-free click reaction, and directly incorporated into the LNP composition (Pep LNPs)...
March 23, 2024: Advanced Science (Weinheim, Baden-Wurttemberg, Germany)
https://read.qxmd.com/read/38519710/mechanisms-and-therapeutic-prospect-of-the-jak-stat-signaling-pathway-in-liver-cancer
#10
REVIEW
JunJun Jia, Xuelian Zhou, Qingfei Chu
Liver cancer (LC) poses a significant global health challenge due to its high incidence and poor prognosis. Current systemic treatment options, such as surgery, chemotherapy, radiofrequency ablation, and immunotherapy, have shown limited effectiveness for advanced LC patients. Moreover, owing to the heterogeneous nature of LC, it is crucial to uncover more in-depth pathogenic mechanisms and develop effective treatments to address the limitations of the existing therapeutic modalities. Increasing evidence has revealed the crucial role of the Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway in the pathogenesis of LC...
March 22, 2024: Molecular and Cellular Biochemistry
https://read.qxmd.com/read/38517376/a-pyrimidine-metabolism-related-signature-for-prognostic-and-immunotherapeutic-response-prediction-in-hepatocellular-carcinoma-by-integrating-analyses
#11
JOURNAL ARTICLE
Shihang Zhang, Ouyang Qin, Shu Wu, Huanming Xu, Wei Huang, Song Hailiang
BACKGROUND: Hepatocellular carcinoma (HCC), with discouraging morbidity and mortality, ranks as one of the most prevalent tumors worldwide. Pyrimidine metabolism is a critical process that regulates DNA and RNA synthesis in cells. It is imperative to investigate the significance of pyrimidine metabolism in liver cancer. METHODS: Transcriptome and clinical data were downloaded from the TCGA database and the GEO database. The genes related to pyrimidine metabolism were sourced from the MSigDB...
March 15, 2024: Aging
https://read.qxmd.com/read/38516783/combining-a-glycolysis%C3%A2-related-prognostic-model-based-on-scrna%C3%A2-seq-with-experimental-verification-identifies-zfp41-as-a-potential-prognostic-biomarker-for-hcc
#12
JOURNAL ARTICLE
Yu Teng, Jianrong Xu, Yaoqun Wang, Ningyuan Wen, Hui Ye, Bei Li
Hepatocellular carcinoma (HCC) is a common malignancy with a poor prognosis, and its heterogeneity affects the response to clinical treatments. Glycolysis is highly associated with HCC therapy and prognosis. The present study aimed to identify a novel biomarker for HCC by exploring the heterogeneity of glycolysis in HCC. The intersection of both marker genes of glycolysis‑related cell clusters from single‑cell RNA sequencing analysis and mRNA data of liver HCC from The Cancer Genome Atlas were used to construct a prognostic model through Cox proportional hazard regression and the least absolute shrinkage and selection operator Cox regression...
May 2024: Molecular Medicine Reports
https://read.qxmd.com/read/38514270/-new-progress-in-the-first-line-treatment-of-advanced-hepatocellular-carcinoma
#13
JOURNAL ARTICLE
C H Zhang, D Y Yao, S Q Liu, L L Yang, Z J Jin
Hepatocellular carcinoma is a kind of cancer with a strong invasion, a high incidence rate and mortality, and a poor prognosis. At the time of diagnosis, most patients are already in the advanced stages of a tumor and have lost the chance for radical surgical treatment. Advanced hepatocellular carcinoma treatment has a gradual transition from systemic chemotherapy to targeted therapy, immunotherapy, and combination therapy, especially immune checkpoint inhibitor-based immunotherapy combination therapy, such as combination with bevacizumab monoclonal antibodies and other drugs, or combination with TACE, HAIC, radiotherapy, ablation, and other treatment methods...
February 20, 2024: Zhonghua Gan Zang Bing za Zhi, Zhonghua Ganzangbing Zazhi, Chinese Journal of Hepatology
https://read.qxmd.com/read/38513753/integration-of-ethanol-and-the-immune-modulator-curcumin-for-immuno-ablation-of-hepatocellular-carcinoma
#14
JOURNAL ARTICLE
Bo Yu, Kijung Kwak, Robert J Lewandowski, Dong-Hyun Kim
PURPOSE: Immuno-ethanol ablation using an ethanol and immune adjuvant formulation is investigated as a potent immuno-ablation approach that can achieve an enhanced anti-cancer effect in the treatment of hepatocellular carcinoma (HCC). MATERIALS AND METHODS: Ethanol concentration- and exposure time-dependent cellular responses were investigated. Curcumin was combined with ethanol as an immuno-ablation agent. Cellular uptake of curcumin, cancer cell killing, and inflammatory markers of ethanol-curcumin treatment were characterized...
March 19, 2024: Journal of Vascular and Interventional Radiology: JVIR
https://read.qxmd.com/read/38508240/fasn-mediated-fatty-acid-biosynthesis-remodels-immune-environment-in-clonorchis-sinensis-infection-related-intrahepatic-cholangiocarcinoma
#15
JOURNAL ARTICLE
Lixia Xu, Ying Zhang, Zhilong Lin, Xinlang Deng, Xiaoxue Ren, Mingle Huang, Shangru Li, Qianying Zhou, Fei Fang, Qingxia Yang, Gaomin Zheng, Zebin Chen, Zhongdao Wu, Xi Sun, Jie Lin, Jingxian Shen, Jianping Guo, Xiaoxing Li, Tianchen Xue, Jing Tan, Xiaoxuan Lin, Li Tan, Hong Peng, Shunli Shen, Sui Peng, Shaoqiang Li, Lijian Liang, James M Cleary, Jiaming Lai, Yubin Xie, Ming Kuang
BACKGROUND & AIMS: Intrahepatic cholangiocarcinoma (ICC) is the second most common primary liver cancer with high lethality. Clonorchis sinensis (C. sinensis) infection is an important risk factor for ICC. Here we investigated the clinical impact and underlying molecular characteristics of C. sinensis-infected ICC. METHODS: We performed single-cell RNA sequencing, whole exome sequencing, RNA-sequencing, metabolomics and spatial transcriptomics in 251 ICC patients from three medical centers...
March 18, 2024: Journal of Hepatology
https://read.qxmd.com/read/38507233/anoikis-related-lncrna-signature-predicts-prognosis-and-is-associated-with-immune-infiltration-in-hepatocellular-carcinoma
#16
JOURNAL ARTICLE
Jiahong Zhu, Wenjing Zhao, Junkai Yang, Cheng Liu, Yilang Wang, Hui Zhao
Anoikis is a programmed cell death process triggered when cells are dislodged from the extracellular matrix. Numerous long noncoding RNAs (lncRNAs) have been identified as significant factors associated with anoikis resistance in various tumor types, including glioma, breast cancer, and bladder cancer. However, the relationship between lncRNAs and the prognosis of hepatocellular carcinoma (HCC) has received limited research attention. Further research is needed to investigate this potential link and understand the role of lncRNAs in the progression of HCC...
March 11, 2024: Anti-cancer Drugs
https://read.qxmd.com/read/38501260/peroxisome-proliferator-activated-receptor-agonists-and-antagonists-an-updated-patent-review-2020-2023
#17
REVIEW
Barbara De Filippis, Arianna Granese, Alessandra Ammazzalorso
INTRODUCTION: The search for novel compounds targeting Peroxisome Proliferator-Activated Receptors (PPARs) is currently ongoing, starting from the previous successfully identification of selective, dual or pan agonists. In last years, researchers' efforts are mainly paid to the discovery of PPARγ and δ modulators, both agonists and antagonists, selective or with a dual-multitarget profile. Some of these compounds are currently under clinical trials for the treatment of primary biliary cirrhosis, nonalcoholic fatty liver disease, hepatic, and renal diseases...
March 19, 2024: Expert Opinion on Therapeutic Patents
https://read.qxmd.com/read/38501000/comprehensive-analysis-of-adgre5-gene-in-human-tumors-clinical-relevance-prognostic-implications-and-potential-for-personalized-immunotherapy
#18
JOURNAL ARTICLE
Xiangjian Zhang, Xinxin Zhang, Qiuhui Yang, Ruokuo Han, Walaa Fadhul, Alisha Sachdeva, Xianbo Zhang
PURPOSE: The Adhesion G protein receptor E5 (ADGRE5) gene is involved in a wide range of biological functions in human tumors; however, its specific molecular mechanism and significance in the analysis of human tumors have not yet been determined. Here, we provide a comprehensive genomic architecture of ADGRE5 in the tumor immune microenvironment and its clinical relevance across a broad range of solid tumors. METHODS: In this study, we used publicly available bioinformatics databases, with a primary focus on The Cancer Genome Atlas (TCGA) database and GTEx data, to conduct a comprehensive analysis of the impact on patient prognosis associated with ADGRE5...
March 30, 2024: Heliyon
https://read.qxmd.com/read/38496356/exploring-the-role-of-naa40-in-immune-infiltrates-and-prognostic-prediction-in-hepatocellular-carcinoma
#19
JOURNAL ARTICLE
Tong Zhou, Jun Cao, Qingqin Tang, Jieyu Jin, Yuting Liang, Bin Feng
NAA40 belongs to the N-terminal acetyltransferase (NATs) family, responsible for protein N-terminal modification, and it exerts crucial roles across various cancers. However, its impact on patient prognosis and immune infiltration in hepatocellular carcinoma (HCC) remains elusive. To address this, our study delved into the comprehensive analysis of NAA40 in the context of cancer. Our pan-cancer analysis unveiled elevated NAA40 expression in multiple tumor types, including BLCA, BRCA, CHOL, COAD, ESCA, HNSC, LIHC, LUAD, LUSC, STAD, and THCA...
2024: American Journal of Clinical and Experimental Immunology
https://read.qxmd.com/read/38495258/hepatocellular-carcinoma-advances-in-systemic-therapy
#20
REVIEW
Insija Ilyas Selene, Merve Ozen, Reema A Patel
Hepatocellular carcinoma (HCC) is a prevalent primary liver cancer, representing over 90% of cases globally and ranking as the third leading cause of cancer-related death. This article reviews the evolving landscape of systemic therapies for advanced HCC, emphasizing recent advancements and their impact on patient outcomes. The advent of molecular targeted therapies has transformed HCC management, with sorafenib being the first FDA-approved molecular targeted therapy, setting a standard for a decade. However, recent breakthroughs involve the combination of atezolizumab and bevacizumab, demonstrating superior outcomes over sorafenib, leading to FDA approval in 2020...
February 2024: Seminars in Interventional Radiology
keyword
keyword
113389
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.